Delving into the Latest Updates on Coramsine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

IL-6R

Mechanism

IL-6 receptor family antagonists

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

MelanomaNeoplasmsRenal Cell Carcinoma

Originator Organization

Curacel International Pty Ltd

Active Organization-

Inactive Organization

Creative Eye Ltd.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Coramsine is a novel chemotherapeutic agent isolated from Solanum linnaeanum (devil's apple). Topical treatment provides clinical benefit for skin tumors. To evaluate the potential broader applicability of the drug, its in vivo anticancer efficacy in a murine model of malignant mesothelioma and its mode of action were investigated. Systemic administration of coramsine slowed tumor growth and prolonged survival time. Importantly, the antitumor efficacy of coramsine was enhanced when treatment was combined with stimulation of innate immunity using unmethylated CpG-containing oligodeoxynucleotides (ODNs). Combination treatment further slowed tumor growth and provided a survival benefit. Coramsine seems to kill tumor cells by direct cell lysis. Using 2 different assays to detect apoptosis (caspase activation and DNA fragmentation), we found no evidence that coramsine induces any form of programmed cell death. The fact that the efficacy of coramsine is potentiated by CpG ODNs suggests that coramsine-induced cell death is an immunologic null event.

100 Deals associated with Coramsine

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma	Phase 2	AU	Creative Eye Ltd.	-
Neoplasms	Phase 2	US	Creative Eye Ltd.	-
Renal Cell Carcinoma	Phase 2	AU	Creative Eye Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2006	Phase 1	HR-positive/HER2-low Solid Tumors	27	Coramsine	(foxajchiws) = yusglabuaa uwrgeaaacq (vtwyhvvils )	-	20 Jun 2006
ASCO2005	Phase 1	HR-positive/HER2-low Solid Tumors	19	Coramsine	(zogavdtuql) = uzzwbaxbcy memqgplses (jnlmdxohrx )	-	01 Jun 2005